A Phase 1 interventional study of MK-2060 in End-Stage Renal Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 1, and was the 8th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in combination with a commonly used P2Y12 receptor inhibitor, clopidogrel, in ESRD patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8.
Drug: MK-2060
MK-2060 administered via IV infusion
Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)
Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding.
Time frame: Up to approximately 104 days
Number of Participants Who Experience One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 104 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 8 days
Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060
The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.
Time frame: Day 1: predose, and 1, 12, 24, and 48 hours postdose. Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.
Maximum Plasma Concentration (Cmax) of MK-2060
Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.
Time frame: Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Plasma Concentration at 168 Hours (C168) of MK-2060
C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose.
Time frame: Days 1 and 8: 168 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of MK-2060
Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.
Time frame: Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Terminal Half Life (t1/2) of MK-2060
T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium.
Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Clearance at Steady State (CLss) of MK-2060
CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state.
Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Apparent Volume of Distribution at Steady State (Vss) of MK-2060
Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state.
Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Time to Hemostasis Following MK-2060 Treatment
Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site \[i.e., arteriovenous (AV) fistula or AV graft\] until adequate hemostasis has been obtained for both the arterial and venous sites.
Time frame: Up to approximately 15 days
| Milestone | MK-2060 |
|---|---|
| Started | 12 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding.
| Participants | MK-2060 |
|---|---|
| Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | MK-2060 |
|---|---|
| Number of Participants Who Experience One or More AEs | 6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | MK-2060 |
|---|---|
| Number of Participants Who Discontinue Study Intervention Due to an AE | 0 |
The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.
| hour*nmol/L | MK-2060 |
|---|---|
| Week 1 | 2040 ± 27.5 |
| Week 2 | 9060 ± 40.5 |
Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.
| nmol/L | MK-2060 |
|---|---|
| Week 1 | 29.7 ± 19.9 |
| Week 2 | 87.6 ± 24.2 |
C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose.
| nmol/L | MK-2060 |
|---|---|
| Week 1 | 43.1 ± 26.7 |
| Week 2 | 34.3 ± 66.2 |
Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.
| Hours | MK-2060 |
|---|---|
| Week 1 | 1.03 (0.75 to 1.25) |
| Week 2 | 1.07 (0.90 to 12.00) |
T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium.
| Hours | MK-2060 |
|---|---|
| Terminal Half Life (t1/2) of MK-2060 | 402 ± 31.5 |
CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state.
| L/hour | MK-2060 |
|---|---|
| Clearance at Steady State (CLss) of MK-2060 | 0.0170 ± 25.6 |
Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state.
| Liters | MK-2060 |
|---|---|
| Apparent Volume of Distribution at Steady State (Vss) of MK-2060 | 6.34 ± 33.3 |
Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site \[i.e., arteriovenous (AV) fistula or AV graft\] until adequate hemostasis has been obtained for both the arterial and venous sites.
| Minutes | MK-2060 |
|---|---|
| Time to Hemostasis Following MK-2060 Treatment | 11.0 (6.97 to 15.1) |
Collected over Run-in (Clopidogrel 75 mg) arm: Approximately 14 days MK-2060 25 mg IV/Clopidogrel 75 mg arm: Up to approximately 108 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in (Clopidogrel 75 mg) | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| MK-2060 25 mg IV/Clopidogrel 75 mg | 0/12 (0%) | 3/12 (25%) | 5/12 (41.7%) |
| Event | Run-in (Clopidogrel 75 mg) | MK-2060 25 mg IV/Clopidogrel 75 mg |
|---|---|---|
| OsteomyelitisInfections and infestations | 0/12 | 1/12 |
| PneumoniaInfections and infestations | 0/12 | 1/12 |
| Staphylococcal sepsisInfections and infestations | 0/12 | 1/12 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 0/12 | 1/12 |
| SyncopeNervous system disorders | 0/12 | 1/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 |
| Event | Run-in (Clopidogrel 75 mg) | MK-2060 25 mg IV/Clopidogrel 75 mg |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/12 | 1/12 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 0/12 |
| HeadacheNervous system disorders | 0/12 | 1/12 |
| Metabolic encephalopathyNervous system disorders | 0/12 | 1/12 |
| AgitationPsychiatric disorders | 0/12 | 1/12 |
| Renal hypertensionRenal and urinary disorders | 0/12 | 1/12 |
| Cold sweatSkin and subcutaneous tissue disorders | 0/12 | 1/12 |
| HypotensionVascular disorders | 0/12 | 1/12 |
| Age, Continuous(Years) | MK-2060 |
|---|---|
| Mean | 57.3 ± 8.2 |
| Sex: Female, Male(Participants) | MK-2060 |
|---|---|
| Female | 0 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | MK-2060 |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | MK-2060 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from May 2022 to primary completion in Feb 2023, 8 months.
Results were first posted in Oct 2024, 1 year 8 months after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060